Overall, in tumour cells, TIMD4 acts as an oncogenic factor that promotes the progression of renal cell carcinoma and can serve as a novel anti‐cancer target to be used in combination with other anti‐cancer drugs to enhance their efficacy. This evidence concerns the gene TIMD4 and renal cell carcinoma.